Benjamin Nicholson

Company: Xilio Therapeutics Inc.

Job title: VP, Drug Discovery

Seminars:

XTX501, a Tumor-Activated PD1/IL2 Bispecific Molecule, Designed to Stimulate & Expand Antigen-Experienced T cells in the Tumor Microenvironment 11:40 am

Design of XTX501 and key components Rationale for targeting IL-2 to PD1-positive T cells and importance of masking Overview of preclinical data including PK and tolerability in non-human primatesRead more

day: Conference Day One